Last reviewed · How we verify

NCT06145165

A Analgesic Study of Adductor Canal &IPACK Block with Liposomal Bupivacaine in Knee Arthroplasty

Status unknown Phase 4 Last updated 23 September 2024
What this trial tests

Phase 4 trial testing Nerve block with ropivacaine and intravenous analgesia in Liposomal Bupivacaine in 90 participants. Status unknown.

Timeline
10 December 2023
Primary endpoint
31 December 2024
31 December 2024

Quick facts

Lead sponsorNanjing First Hospital, Nanjing Medical University
PhasePhase 4
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment90
Start date10 December 2023
Primary completion31 December 2024
Estimated completion31 December 2024
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Nanjing First Hospital, Nanjing Medical University

Who can join

Adults 18 to 79, any sex, with Liposomal Bupivacaine or Postoperative Recovery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To study the effectiveness of ACB and iPACK block with liposomal bupivacaine for postoperative analgesia in patients undergoing knee arthroplasty

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Liposomal Bupivacaine

Currently open trials in the same condition.

Other Nanjing First Hospital, Nanjing Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06145165.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing